摘要
Abstract
The low density lipoprotein cholesterol plays an important role in occurrence and development of atherosclerotic cardiovascular diseases (ASCVD).Statins preparation is the foundation that prevention and treatment of ASCVD,however,for some patients,the lipid-lowering effect is not ideal when using the adequate statins but have a higher risk of cardiovascular disease,with familial hypercholesterolemia or can’t tolerate the side effects of enough statin treatment need other new effective and safe lipid-lowering drug.PCSK9 inhibitor can significantly elevate the surface of LDL-C receptor of liver cells and bond more LDL-C to decrease the level of LDL-C.Multiple monoclonal antibodie of target PCSK9 protein inhibitors have been published in succession.A lot of basic and clinical research have been con-firmed that PCSK9 inhibitors can significantly reduce blood LDL-C and have good safety and tolerability.Preliminary research data show that PCSK9 inhibitors can reduce the cardiovascular events,the results are encouraging.关键词
胆固醇/家族性高胆固醇血症/降胆固醇药/PCSK9靶向抑制剂/心血管疾病Key words
Cholesterol/Familial hypercholesterolemia/Cholesterol-lowering drugs/Target PCSK9 protein inhibitors/Cardiovascular disease分类
医药卫生
